Organigram Global (OGI) Net Income towards Common Stockholders (2018 - 2026)
Organigram Global (OGI) posted quarterly Net Income towards Common Stockholders of $13.9 million for Q1 2026, down 53.06% year-over-year from $29.6 million in Q1 2025, and up 176.71% quarter-over-quarter from $5.0 million in Q4 2025.
Organigram Global (OGI) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Net Income towards Common Stockholders for 7 consecutive years, with $13.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 53.06% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $48.5 million (up 96.19% YoY), while the FY2025 annual figure was $4.5 million, changed N/A from the prior year.
- Net Income towards Common Stockholders rose to $13.9 million in Q1 2026 per OGI's latest filing, from $5.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $29.6 million in Q1 2025 and bottomed at -$4.9 million in Q4 2024.
- Historically, Net Income towards Common Stockholders has averaged $10.9 million across 3 years, with a median of $9.5 million in 2025.
- Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders soared 203.1% — and 2026, when it sank 53.06%.
- Organigram Global's Net Income towards Common Stockholders stood at -$4.9 million in 2024, then soared by 203.1% to $5.0 million in 2025, then jumped by 176.71% to $13.9 million in 2026.
- Business Quant data shows OGI's Net Income towards Common Stockholders at $13.9 million in Q1 2026, $5.0 million in Q4 2025, and $29.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Organigram Global | 151.93 Mn | 151.81 Mn | 28.97 Mn | 27.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.89 Mn |
| Dec 31, 2025 | 5.02 Mn |
| Mar 31, 2025 | 29.59 Mn |
| Dec 31, 2024 | -4.87 Mn |
| May 31, 2021 | -104.73 Mn |
| Feb 28, 2021 | 100.73 Mn |
| Nov 30, 2020 | -34.34 Mn |
| Aug 31, 2020 | -166.07 Mn |
| May 31, 2020 | -64.27 Mn |
| Feb 29, 2020 | -6.83 Mn |
| Nov 25, 2019 | 15.25 Mn |
| May 31, 2019 | -7.60 Mn |
| Nov 30, 2018 | -38,000.00 |
| May 31, 2018 | -1.27 Mn |